Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial - Wikidata - wikimedia - TriplyDB

Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial

Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial

http://www.wikidata.org/entity/Q28251568

about

Antiviral drugs for viruses other than human immunodeficiency virus The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis Direct acting antivirals for the treatment of chronic viral hepatitis Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B Safety and efficacy of telbivudine for the treatment of chronic hepatitis B Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.Severe acute exacerbation of chronic hepatitis B: a unique presentation of a common disease.Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B.Antiviral treatment of chronic hepatitis B virus (HBV) infections A low viral load predicts a higher initial virologic response to adefovir in patients with Lamivudine-resistant chronic hepatitis B.52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection.Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.Telbivudine in the treatment of chronic hepatitis B.Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis.Safety and efficacy of entecavir for the treatment of chronic hepatitis B.Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.Comparison of the Effects of Telbivudine and Entecavir Treatment on Estimated Glomerular Filtration Rate in Patients with Chronic Hepatitis B.Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study.Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients.Evaluation and treatment of the patient coinfected with hepatitis B and HIV.Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.Hepatitis B and liver transplantation: 2008 update.Management of patients with decompensated hepatitis B virus associated [corrected] cirrhosis.Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48.A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model.Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides.Treatment of chronic hepatitis B: focus on telbivudine.Chronic hepatitis B: who to treat and which choice of treatment?Benefits and risks of combination therapy for hepatitis B.Then and now: the progress in hepatitis B treatment over the past 20 years.Predictors of treatment response in chronic hepatitis B.Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study Hepatitis B therapies and antiviral resistance detection and management.On-treatment monitoring of chronic hepatitis B virus infection: an Asian-Pacific perspective.A review of oral antiretroviral therapy for the treatment of chronic hepatitis B.

P2860

Q24635330-16047F79-3941-476F-BB67-DF0083284F73 Q27016075-ED94C0BC-C1E7-4CA1-AB77-5556F2641D1E Q27022216-F3B2695A-B79C-42F3-A891-4358F7DB4E63 Q27030828-5A3B1553-EF97-416C-A5B2-7ACDC7BEF1E7 Q28972486-109AA78E-7321-4658-93CA-028F95F9DE33 Q30391932-EAEF83C2-9B89-41AA-8457-C61774D1E603 Q30829485-8DC3B847-9745-4215-B571-3A2E1BECEE3C Q33385813-D2ECAE1A-2FF2-4DDE-8233-D7C541AF212D Q33676349-FEBC3F5B-9F55-44E1-B176-7507AA3A052C Q33819098-98DAFB52-203A-493F-8564-59E77513D594 Q34223779-549F10ED-322C-435A-AFD2-46CFA660E1B0 Q34494102-56EC5697-770D-4D1D-8CF8-031375863B31 Q34579911-CD38767E-EEB9-4EB7-9E2D-05595BBE8030 Q34594403-5FA783FD-5F0B-4050-996B-3FB13C02AAD9 Q34601513-66720B99-C892-4A03-ABF0-54E9D0D12C01 Q34604670-5A814B32-B095-46E8-83DF-E7DFDD46FE59 Q34999403-6520BA95-B400-4672-A7DE-88C7D35DE7FB Q35026611-BEC31A64-7D45-48EB-AFAC-D71958AB1E44 Q35132805-B6DBC483-D786-40D0-9E93-546B23B9D37D Q35833216-E5519574-DBCE-42FE-B40F-7CABBF597388 Q36223439-73BBCF11-B89F-4E2C-A050-C122A6EFEB44 Q37138794-D8194054-2A86-4137-BBA4-D0F6E7F78B73 Q37149701-C381582E-EB85-4F08-8206-0BCB179A0CB0 Q37216879-FECB646F-4C12-423C-9A5A-D7DA19A6C7F7 Q37278241-E7866EF3-0DA9-4E4B-8C59-B0A515385EAC Q37279114-CDDEE762-FFB1-4A78-9D65-9F49162AB340 Q37282575-63126E65-E7D4-4C16-A8BA-3640B6A7B244 Q37334120-D7B3F488-F5C8-4FEB-9AFA-0C05A1997DC5 Q37380067-8F58CAF7-DB95-4F95-A4BC-93B664891C55 Q37387494-12E63E53-3E5F-4F6A-A718-CC86CD63B9BD Q37399490-698D098E-FAC4-41D5-9042-77B745589599 Q37432074-D0A5E952-B01A-4794-B1A2-BA3F3E0A878C Q37432086-ADC27302-D212-4B63-822D-15AABBF34CD3 Q37462525-D294EDF6-235E-4023-8451-C7F92070A594 Q37581346-5D361BC6-76A2-4A0F-BEDB-0297223DCC8F Q37620332-ECE1FA3D-3D89-4BE8-A1D2-8F669253AE38 Q37624126-7D7B3CC4-BFF6-4222-8C70-D51AD8B77344 Q37636111-AA7450D1-2696-4120-85B7-F2856D89719E Q37764961-43B7BE22-D451-441F-8C2D-7BD9B7E66470 Q37768591-CBF79ED6-E7DA-41B6-BFAE-FDEC9836E369

P2860

Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial

http://www.wikidata.org/entity/Q28251568

description

2007 nî lūn-bûn

@nan

2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Treatment of hepatitis B e ant ...... r adefovir: a randomized trial

@ast

Treatment of hepatitis B e ant ...... r adefovir: a randomized trial

@en

Treatment of hepatitis B e ant ...... r adefovir: a randomized trial

@nl

type

label

Treatment of hepatitis B e ant ...... r adefovir: a randomized trial

@ast

Treatment of hepatitis B e ant ...... r adefovir: a randomized trial

@en

Treatment of hepatitis B e ant ...... r adefovir: a randomized trial

@nl

prefLabel

Treatment of hepatitis B e ant ...... r adefovir: a randomized trial

@ast

Treatment of hepatitis B e ant ...... r adefovir: a randomized trial

@en

Treatment of hepatitis B e ant ...... r adefovir: a randomized trial

@nl

P1433

Q28251568-6F0ED746-16D4-4826-841A-5F53B30F1E19

P1476

Q28251568-43C1E0A4-CC0B-45F2-96E7-E0BFA63EA4CB

P2093

Q28251568-0EDE91B5-9829-4921-BE01-FD6D47BE0D0A

Q28251568-22EC8F42-DCA5-4AD0-AF4A-5F4E88007E64

Q28251568-301077F5-C586-4861-96E5-5923E4DA64B6

Q28251568-3F1B0555-E14E-4467-820A-83E85CF676DC

Q28251568-4D58B671-4DF5-4669-A54D-60560CC59C65

Q28251568-5508287C-C0AD-41D9-8945-F1199F89B824

Q28251568-625EE4B0-A3E8-4506-B436-083EE23BAE0D

Q28251568-6E2F33E7-7120-4E38-BB56-E64751B048AE

Q28251568-85431120-F5F7-4B24-9077-DDB0B4372441

Q28251568-932987B4-5B97-4F7B-8BB8-709E1B582E0C

P304

Q28251568-70FEFEBE-9C5B-479C-A7BE-91513F1C6AD4

P31

Q28251568-C2BC591E-BD44-41B4-BE90-C46115161CE3

P3181

Q28251568-6F17B6BB-82F0-4661-AFF0-4962FE281C93

P356

Q28251568-8A7A81C1-4BF1-40D5-A5B2-88E68CF84BE6

P407

Q28251568-5BF256F4-38DE-43EC-8C51-964ED95E4747

P433

Q28251568-1B13A81B-DA0E-4698-8CC4-DB0AD3F61807

P478

Q28251568-1AE04FA2-5997-4F75-B4A0-1525EE6C4FCF

P50

Q28251568-68DDFC43-336C-4FBA-B5CA-0B9D4ED76695

P577

Q28251568-66BF39AF-B48F-487D-B7B2-CF02FC746C49

P698

Q28251568-7CBA05DE-2A3F-411B-B2F4-5C02479CD1A0

P3181

P356

0003-4819-147-11-200712040-00183

P1433

Annals of Internal Medicine

P1476

Treatment of hepatitis B e ant ...... r adefovir: a randomized trial

@en

P2093

E Jenny Heathcote

http://www.w3.org/2001/XMLSchema#string

George Harb

http://www.w3.org/2001/XMLSchema#string

Gerald Y Minuk

http://www.w3.org/2001/XMLSchema#string

Henry L Y Chan

http://www.w3.org/2001/XMLSchema#string

Lennox Jeffers

http://www.w3.org/2001/XMLSchema#string

Mong Cho

http://www.w3.org/2001/XMLSchema#string

Natalie Bzowej

http://www.w3.org/2001/XMLSchema#string

Nathaniel A Brown

http://www.w3.org/2001/XMLSchema#string

Patrick Marcellin

http://www.w3.org/2001/XMLSchema#string

Ralf Kaiser

http://www.w3.org/2001/XMLSchema#string

P304

745-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4087516

http://www.w3.org/2001/XMLSchema#string

P356

10.7326/0003-4819-147-11-200712040-00183

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

147

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17909201

http://www.w3.org/2001/XMLSchema#string